# Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

> **NCT00633789** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 597 (actual)

## Conditions studied

- Advanced Non-small Cell Lung Cancer
- Transitional Cell Carcinoma
- Soft Tissue Sarcoma
- Gastric/Esophageal Adenocarcinoma
- Pancreatic Cancer Including Ampulla of Vater

## Interventions

- **DRUG:** brivanib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00633789
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2012-02
- **Final completion:** 2012-12
- **Target enrollment:** 597 (ACTUAL)
- **Last updated:** 2015-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00633789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00633789, "Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00633789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*